Regulatory
PCAC Convenes for Crucial Vote on 7 Peptides
Today, July 23, 2026, marks the first day of the highly anticipated FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. The two-day hearing will determine whether seven popular peptides—BPC-157, TB-500, KPV, and MOTs-c today, followed by DSIP, Semax, and Epitalon on July 24—can be legally compounded by 503A pharmacies. While these peptides were pulled off the FDA's restricted Category 2 list earlier this year, FDA scientists released briefing reports ahead of the meeting recommending against their approval for compounding. The scientists cited insufficient human clinical data and safety concerns compared to established FDA-approved drugs.
Political
HHS Leadership vs. FDA Scientists
The PCAC hearings are shaping up to be a major flashpoint between the traditional medical establishment and Health and Human Services Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda. Kennedy has aggressively advocated for lifting restrictions on these naturally occurring peptides, setting up a political clash with FDA career scientists who warn against the risks of an unregulated wellness and longevity market.
Legal
Novo Nordisk Sues Eli Lilly as GLP-1 Crackdowns Continue
On July 21, 2026, Novo Nordisk filed a federal lawsuit in the District of New Jersey against Eli Lilly, accusing Lilly of misleading direct-to-consumer advertising for its GLP-1 drugs Zepbound and Mounjaro. While this is a private Lanham Act dispute over dosing comparisons, the backdrop is a broader government crackdown on GLP-1 and peptide marketing. The FDA's Office of Prescription Drug Promotion recently directed approximately 30 warning letters to telehealth and compounding operators for misleading GLP-1 promotional claims, demonstrating heightened regulatory scrutiny over how these drugs are represented online.
Market Watch
Telehealth Eyes a $30 Billion Prize
Financial analysts and major telehealth platforms are watching the FDA's PCAC vote closely. A July 20 report highlighted that major telehealth firms, including Hims & Hers, Ro, and Solace, are positioning themselves to enter the peptide-compounding market if the committee votes favorably. Needham Research recently estimated the total addressable peptide market at nearly $30 billion. Hims & Hers Chief Medical Officer Dr. Anant Vinjamoori is scheduled to testify at today's hearing, underscoring the massive commercial stakes for online prescribers.
Closing Takeaway for Compliance Posture
While the PCAC decision directly affects 503A compounding pharmacies, research-use-only (RUO) suppliers must remain on high alert. If these peptides are approved for compounding, commercial telehealth demand will surge, potentially blurring the lines for RUO suppliers whose products could be diverted into human-use pipelines. Conversely, if the FDA upholds the ban, gray-market demand for RUO peptides will skyrocket, drawing intense FDA and FTC enforcement on marketing claims and website labeling. Ensure all strict RUO disclaimers, institutional verification processes, and Material Safety Data Sheets (MSDS) are vigorously enforced.